Full Breakdown
Surge in Chinese Drug Makers' Out-Licensing Deals in 2025
1/8/2026, 7:32:41 AM
Record-Breaking Licensing Agreements
In 2025, Chinese drug makers achieved a significant milestone, with out-licensing deals more than doubling from the previous year to a record high of US$135.7 billion. This surge was driven by numerous multibillion-dollar agreements between firms listed in Hong Kong and mainland China and major global pharmaceutical companies. The National Medical Products Administration (NMPA), China's drug regulatory authority, reported that 157 out-licensing deals were signed in 2025, compared to 94 deals worth US$51.9 billion in 2024.
Out-licensing agreements allow a company to grant another firm exclusive rights to further develop, manufacture, and commercialize a drug that has entered clinical trials. In return, the original company receives upfront payments, milestone fees, and royalties on future sales.
Notable Transactions
Among the prominent deals in 2025 was a US$13 billion contract between Suzhou-based GeneQuantum and US-based Biohaven Pharmaceutical, along with South Korea's AimedBio. This agreement focused on antibody drug conjugates, a type of cancer medication that utilizes antibodies to target and kill tumor cells. Additionally, Shenyang-based 3SBio entered into a US$6 billion licensing agreement with Pfizer for its SSGJ-707 cancer drug in May.
Implications for the Pharmaceutical Industry
The rapid increase in out-licensing deals reflects a growing trend of collaboration between Chinese pharmaceutical companies and international firms. This shift not only enhances the global reach of Chinese drug makers but also signifies their increasing competitiveness in the global pharmaceutical landscape. The influx of capital from these agreements may further accelerate research and development efforts within China, potentially leading to innovative treatments and therapies.
Criticism & Opposition
Despite the positive outlook, some industry experts express concerns regarding the sustainability of such rapid growth in licensing deals. Critics argue that the focus on large-scale agreements may overshadow the need for robust internal development capabilities within Chinese firms. They caution that reliance on external partnerships could hinder long-term innovation and self-sufficiency in the domestic pharmaceutical sector.
Official Statements & Responses
The NMPA highlighted the importance of these licensing agreements in fostering innovation and collaboration within the pharmaceutical industry. Officials emphasized that such partnerships are crucial for advancing drug development and improving patient access to new therapies.
What's Next
As the trend of out-licensing continues, industry stakeholders will be closely monitoring the outcomes of these agreements, particularly in terms of drug development timelines and market access. Future collaborations may also expand into new therapeutic areas, further shaping the landscape of the global pharmaceutical industry.
